Hot Investor Mandate: USA-Based Investment Firm Actively Seeks to Invest in Therapeutics Companies or Devices/Diagnostics With a Therapeutic Component

25 Aug

A venture capital investment firm founded in 2020 by experienced investment professionals and headquartered in the USA is currently operating out of its inaugural fund and is actively looking for deal flow. Typical investment size ranges from USD 0.5 million to USD 2 million. Investment strategy at the firm is evolving but currently the firm participates in equity investments only. The firm looks to partner with early-stage companies and is open to global opportunities but will typically focus on opportunities in the United States.

The firm is interested in investing in therapeutics companies, or companies in other sectors that have a therapeutic component. Within therapeutics the firm will consider assets from pre-clinical to pre-IND filing and generally prefers to see some type of proof-of-concept data. Within medical devices and diagnostics, the firm invests in technologies that are pre-commercial and is open to all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will invest in companies throughout all indications including those in orphan diseases.

The firm is open to working with experienced management teams. The firm looks to work with management teams that are ambitious and able to work together and execute well. The firm takes an active role in the companies in which it invests; however, the firm currently only looks to co-invest.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm with Healthtech-Focused Fund Invests in Early-Stage Digital Health Technologies Dedicated to Better Healthcare Delivery

25 Aug

A private investment firm launched a healthtech-focused fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests Up to $50M, Open to All Revenue-Generating Technologies Within Life Sciences & Healthcare with Meaningful Marketplace Validation

25 Aug

A firm based in the USA and investing out of their third fund currently makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $15-$50m per company.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based Pharmaceutical Seeks Global R&D Partnerships and Investment in Drugs, Devices, and More With Strong Interest in Anti-Infectives and Oncology

25 Aug

A listed pharmaceutical company with $5 Billion of assets under management has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area after 2 decades of arduous efforts. The firm is open to global R&D partnerships and investment opportunities.

The firm has a focused interest in finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Eli Lilly Comes to RESI

18 Aug

By Antoinette Lowre, Manager of Business Development, LSN

Eli Lilly joins RESI Boston, September 21-23, providing insight from the large pharma to the RESI community of early-stage players. Eli Lilly is committed to creating high-quality medicines through every aspect of business and the people they serve, stating that “Lilly unites caring with discovery to create medicines that make life better for people around the world.” This is central to Life Science Nation (LSN)’s mission of connecting early-stage life science with capital and channel partners to see healthcare advance. We are thrilled to bring Eli Lilly to RESI to add value to the community and provide new opportunities for investors and founders to gain more exposure to early-stage life science players.

In addition to a Title Sponsorship, Eli Lilly will send a team to source assets within the following sectors and indications:

  1. Genetic Medicine – RNA, Gene-editing, and Gene therapy, including associated delivery technology (e.g. next-gen AAV capsids and non-viral approaches)
  2. Neuroscience, including technology and tools to achieve CNS delivery of therapeutics.
  3. Obesity/Diabetes, including approaches to broaden therapeutic administration routes.

If your product and technology align with these sectors, reach out to us to connect with Eli Lilly at RESI Boston.  Partnering opens soon, so sign up today!

To explore the full breath of Lilly’s interests please visit https://www.lilly.com/partners.

RESI-Boston-2022-Banner-with-lilly-logo-1100px

LSN Partners with Shinhan Square Bridge (S2 Bridge), a Global Startup Acceleration Platform

18 Aug

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claire

Life Sciencen Nation (LSN)’s latest partnership features Shinhan Square Bridge (S2 Bridge), a Startup Acceleration Platform based in Songdo, Incheon Metropolitan City in South Korea. Throughout the past several years, we have collaborated with many Korean organizations to support the global expansion of promising early-stage life science companies. S2 Bridge will bring seven startups to RESI Boston, September 21-23, to be showcased during a 2-hour dedicated pitch session. Below are the participating companies:

LSN’s mission to facilitate connections between life science startups and investors and strategic partners is central to these partnerships, bringing S2 Bridge and their participating startups to increase their visibility to our global ecosystem. Ji Sun (Julia) Lee, CEO of S2 Bridge said, “South Korea’s biotech industry has made significant progress throughout the ongoing pandemic and is only continuing to grow. As global partnerships and collaborations are key to success particularly in the life science industry, we hope that our partnership with LSN and RESI serves as an opportunity to properly showcase Korean startups and their innovativeness to the global market.”

Learn more about S2 Bridge and their partnering organizations:

Shinhan Square Bridge (S2 Bridge) Incheon

With the motto of “One Place, One Platform”, 『Shinhan Square Bridge (S2 Bridge) Incheon』 is a platform that supports the growth of startups in cooperation with government agencies and the private sector. S2 Bridge was established as the first public-private Startup Acceleration Platform in South Korea, with the dream of becoming a global startup innovation growth hub.

S2 Bridge is located in Songdo, a city in South Korea recognized as a global business center and biocluster. Key partnering organizations include Shinhan Financial Group, a leading global financial group that supports an innovative investment ecosystem, and Celltrion, a global biotech company that supports open innovation opportunities to accelerate promising biotech startups, and Incheon Metropolitan City that actively helps to foster the local biotech infrastructure. From the seed to global expansion stage, S2 Bridge focuses on accelerating life science startups based on their innovative technologies. The firm focuses on startups in all fields of life sciences, including novel therapeutics, microbiome, medical devices, and digital health to enter the global market and attract investment.

S2 Bridge operates a one-stop investment platform with Incheon Metropolitan City and Incheon Free Economic Zone Authority (IFEZ) and supports open innovation with Shinhan Financial Group and Celltrion. Moreover, the firm supports networking and content for the expansion of the startup ecosystem by holding global conferences and providing media promotion, among other activities. The firm also provides a working space optimized for the startups’ business growth to all startup members.

Since launching in November 2020, S2 Bridge has discovered and accelerated 155 promising startups with innovative technologies, and achieved investment attraction of 135.4 billion KRW (~$102M USD), a corporate value growth rate of 90.2%, and 252 cases of open innovation and resource linkage with public-private partnership.

Shinhan Financial Group / Shinhan Financial Group Hope Foundation

Shinhan Financial Group was founded in 2001 as the first private financial holding company in Korea and covers the entire financial industry with 15 group companies and continues to make the way for the global dream to become reality through 200 channels in 20 countries.

With the group’s vision of “Easier, More Comfortable, Newer Finance”, the group provides customers with various financial services to improve society as a whole. The group is taking the lead in establishing common value for mankind with the Group’s Environment, Social, Governance (ESG) Slogan of “Do the Right Thing for a Wonderful World” and is continuing the mission of “Benefitting the World through Finance”, taking pride in the group’s 40-year history of innovation.

Shinhan Financial Group Hope Foundation is a leading first-class, non-profit public interest corporation that promotes the sustainable development of companies, foundations, and CSR projects. The goal is to contribute to the development of the local community through supporting education, art and culture, employment support, and helping people with financial vulnerability.

Incheon Metropolitan City / Incheon Free Economic Zone Authority

Incheon Metropolitan City and Incheon Free Economic  Zone Authority (IFEZ) is located in the center of the Northeast Asian Economic Zone (Songdo) and actively works to create an innovative Startup Ecosystem. Based on world-class business infrastructure, the city of Incheon is creating synergy through high-tech industries and collaborations with renowned industries, universities, and research institutes to create a leading global market. Through these efforts, Incheon seeks to leap forward as the world’s largest bio-healthcare complex and lead the 4th industrial revolution. Leading domestic and international bio companies have moved in and are actively engaged in business activities. In the future, Incheon will flourish with synergistic accomplishments through the establishment of a bio-convergence industrial technology complex.

Presenting a new role model for future smart cities and establishing an urban innovation platform, Incheon Metropolitan City and IFEZ seek to become an eco-friendly city where people and nature co-exist.

Celltrion

Celltrion is Korea’s leading global biotechnology company that pioneered antibody biosimilars for the first time in the pharmaceutical industry. Celltrion has made remarkable achievements by pioneering a path that others have not taken, and rapidly grown into a global biotechnology company based on differentiated business strategies such as the development of chemical drugs, new drugs, and the U-Health Care Platform. Through these strategies, Celltrion is growing into a global comprehensive biotechnology company that promotes the value of advancing human health and welfare.

RESI-Boston-2022-Banner-with-lilly-logo-1100px

Partnering Opens Soon

18 Aug

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI Boston is rapidly approaching, and the partnering platform launch is just around the corner. Opening on August 29, attendees will be able to book meetings at our first hybrid event, either meeting in person on September 21-22, or virtually on September 23. As a partnering-focused event, much effort is made to ensure startups can identify and request meetings with investors and strategic partners who are a fit for them. Additionally, attendees can take advantage of the first in-person RESI since January of 2020 to make unexpected connections through ad hoc meetings and networking opportunities.

Sign up for our free partnering tutorials below and register for RESI before partnering opens to have as much time as possible to maximize your partnering experience!

RESI Boston Partnering Tutorial

August 31, Wednesday Sign Up

September 6, Tuesday Sign Up

RESI-Boston-2022-Banner-with-lilly-logo-1100px